H.C. Wainwright reaffirmed a Buy rating on Oncolytics Biotech (NASDAQ:ONCY) shares with a steady price target of $5.00. The stock, currently trading at $0.73 and near its 52-week low, shows potential ...

As our knowledge of science and the human body expands, so too do doctors have more tools at hand when treating cancer. One ...

Merck & Co’s $394 million acquisition of Viralytics has stoked interest in oncolytic viruses, a class of drugs that have been in the shadow of the checkpoint inhibitors and CAR-T therapies that ...

A new report from Novotech reveals the OV market is expanding at pace, with a compounding annual growth rate of 14.2% between 2019 and 2024. More than 95% of ongoing trials involving oncolytic viruses ...

Talimogene laherparepvec (T-VEC) demonstrates efficacy in cutaneous BCC, enhancing resectability and altering immune cell ...

Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech and small to ...

SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor ...

A phase II trial reports success with an innovative immunotherapy for difficult-to-resect basal cell carcinoma, reducing ...

Researchers from Zhengzhou University and affiliated organizations presented the development and preclinical characterization of VVL-12, an oncolytic vaccinia virus (VV) for the treatment of lung ...

Could be used to treat brain tumours Oncolytic viruses are used as an immunotherapy against cancer, where the virus both invades and kills cancer cells, and activates the immune system to attack ...

This comprehensive whitepaper analyzes the evolving landscape of oncolytic virus therapies (OVT), providing critical insights into this transformative approach to cancer treatment. This press ...